Live
Clinical OMICsGLP-1 Drugs Lower Risk of Death by 44% in Obesity and Autoimmune DiseaseCellDeep-sea megafauna co-opts microbial energy metabolism genes to withstand ultra-long starvationCellReplaying germinal center evolution on a quantified affinity landscapeCellXenophagocytosis blockade enhances interspecies chimerismFierceBiotechADA: Pfizer pads case for berobenatide in obesity, adding validation to Metsera buyEndpoints News#ADA26: Pfizer monthly shot shows effect on obesity, diabetesEndpoints News#ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this yearEndpoints NewsLawmakers propose China restrictions; #ASCO26 recap; and moreFierceBiotech‘It looks like this hypothesis will pan out’: Cullinan unveils data building case for autoimmune TCEsAmgenAmgen: A Biotech Giant's Path to Recovery and Growth - AOL.comAmgenAmgen: A Biotech Giant's Path to Recovery and Growth - The Motley Fool
FierceBiotech 2. Apr. 2026

UK signs off on US pharma deal, ensuring tariff reprieve as Britain aims to reattract investments

UK signs off on US pharma deal, ensuring tariff reprieve as Britain aims to reattract investments

Inhalt nicht verfügbar. Bitte die Originalquelle aufrufen.